Advances in the study of Candida albicans gene mutation on azole drug resistance

Yaoxue Xuebao

Volumn 45, Issue 7, 2010, Pages 821-826

  Zhu, Chun Xiang ^a   Gao, Ping Hui ^a   Jiang, Yuan Ying ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Candida albicans; Drug resistance; Gene mutation

Indexed keywords

ERGOSTEROL; PYRROLE;

ANTIFUNGAL RESISTANCE; CANDIDA ALBICANS; GENE DOSAGE; GENE MUTATION; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; STEROL SYNTHESIS;

ANTIFUNGAL AGENTS; AZOLES; CANDIDA ALBICANS; CYTOCHROME P-450 ENZYME SYSTEM; DNA COPY NUMBER VARIATIONS; DRUG RESISTANCE, FUNGAL; FUNGAL PROTEINS; MEMBRANE TRANSPORT PROTEINS; MUTATION; P-GLYCOPROTEIN;

EID: 77956461114     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem [J]. Clin Microbiol Rev, 2007, 20: 133-163.
2. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study [J]. Clin Infect Dis, 2004, 39: 309-317.
3. Onyewu C, Blankenship JR, Del Poeta M, et al. Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei [J]. Antimicrob Agents Chemother, 2003, 47: 956-964.
4. Xu YH, Chen LM, Li CY. Susceptibility of clinical isolates of Candida species to fluconazole and detection of Candida albicans ERG11 mutations [J]. J Antimicrob Chemother, 2008, 61: 798-804.
5. Lamb DC, Kelly DE, Schunck WH, et al. The mutation T315A in Candida albicans sterol 14-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity [J]. J Biol Chem, 1997, 272: 5682-5688.
6. Sanglard D, Ischer F, Koymans L, et al. Amino acid substitutions in the cytochrome P-450 lanosterol 14α-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents [J]. Antimicrob Agents Chemother, 1998, 42: 241-253.
7. Lamb DC, Kelly DE, White TC, et al. The R467K amino acid substitution in Candida albicans sterol 14alpha-demethylase causes drug resistance throush reduced affinity [J]. Antimicrob Agents Chemother, 2000, 44: 63-67.
8. Podust LM, Poulos TL, Waterman MR. Crystal structure of cytochrome P450 14 a-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors [J]. Proc Natl Acad Sci USA, 2001, 98: 3068-3073.
9. Kudo M, Ohi M, Aoyama Y, et al. Effects of Y132H and F145L substitutions on the activity, azole resistance and spectral properties of Candida albicans sterol 14-demethylase P450 (CYP51): a live example showing the selection of altered P450 through interaction with environmental compounds [J]. J Biochem, 2005, 137: 625-632.
10. Dunkel N, Liu TT, Barker KS, et al. A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate [J]. Eukaryot Cell, 2008, 7: 1180-1190.
11. Heilmann CJ, Schneider S, Barker KS, et al. An A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in Candida albicans [J]. Antimicrob Agents Chemother, 2010, 54: 353-359.
12. Yan L, Zhang J, Li M, et al. DNA microarray analysis of fluconazole resistance in a laboratory Candida albicans strain [J]. Acta Biochim Biophys Sin, 2008, 40: 1048-1060.
13. Miyazaki T, Miyazaki Y, Izumikawa K, et al. Fluconazole treatment is effective against a Candida albicans erg3/erg3 mutant in vivo despite in vitro resistance [J]. Antimicrob Agents Chemother, 2006, 50: 580-586.
14. Pierson CA, Jia N, Mo C, et al. Isolation, characterization, and regulation of the Candida albicans ERG27 gene encoding the sterol 3-keto reductase [J]. Med Mycol, 2004, 42: 461-473.
15. Mukhopadhyay K, Prasad T, Saini P, et al. Membrane sphingolipid- ergosterol interactions are important determinants of multidrug resistance in Candida albicans [J]. Antimicrob Agents Chemother, 2004, 48: 1778-1787.
16. Sun WW, Gao PH, Jiang YY, et al. ATP-binding-cassette transporters and fluconazole-resistance of clinical Candida albicans strains [J]. Acad J Second Mil Med Univ, 2008, 29: 1038-1041.
17. Haque A, Rai V, Bahal BS, et al. Allelic variants of ABC drug transporter Cdr1p in clinical isolates of Candida albicans [J]. Biochem Biophys Res Commun, 2007, 352: 491-497.
18. Holmes AR, Tsao S, Ong SW, et al. Heterozygosity and functional allelic variation in the Candida albicans efflux pump genes CDR1 and CDR2 [J]. Mol Microbiol, 2006, 62: 170-186.
19. Shukla S, Saini P, Smiriti, et al. Functional characterization of Candida albicans ABC transporter Cdrlp [J]. Eukaryot Cell, 2003, 2: 1361-1375.
20. Shukla S, Ambudkar SV, Prasad R. Substitution of threonine-1351 in the multidrug transporter Cdrlp of Candida albicans results in hypersusceptibility to antifungal agents and is essential for synergic effects of calcineurin inhibitor FK520 [J]. J Antimicrob Chemother, 2004, 54: 38-45.
21. Gao PH, Cao YB, Jia XM, et al. Drug susceptibilities of yeast cells are affected when expressing mutant Candida albicans drug resistance protein [J]. Int J Antimicrob Agents, 2006, 28: 69-74.
22. Jha S, Karnani N, Dhar SK, et al. Purification and characterization of N-terminal nucleotide-binding domain of an ABC drug transporter of Candida albicans: uncommon cysteine 193 of Walker A is critical for ATP hydrolysis [J]. Biochemistry, 2003, 42: 10822-10832.
23. Loo TW, Bartlett MC, Clarke DM. The "LSGGQ" motif in each nucleotide-domain of human P-glycoportein is adjacent to the opposing Walker A sequence [J]. J Biol Chem, 2002, 277: 41303-41306.
24. Coste A, Selmecki A, Forche A, et al. Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates [J]. Eukaryot Cell, 2007, 6: 1889-1904.
25. Coste A, Turner V, Ischer F, et al. A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans [J]. Genetics, 2006, 172: 2139-2156.
26. Morschhäuser J, Barker KS, Liu TT, et al. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans [J]. PLoS Pathog, 2007, 3: e164.
27. Gaur NA, Manoharlal R, Saini P, et al. Expression of the CDR1 efflux pump in clinical Candida albicans isolates is controlled by a negative regulatory element [J]. Biochem Biophys Res Commun, 2005, 332: 206-214.
28. Selmecki A, Forche A, Berman J. Aneuploidy and isochromosome formation in drug-resistant Candida albicans [J]. Science, 2006, 313: 367-370.
29. Selmecki A, Gerami-Nejad M, Paulson C, et al. An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1 [J]. Mol Microbiol, 2008, 68: 624-641.
30. Denning DW. Echinocandins: a new class of antifungal [J]. J Antimicrob Chemother, 2002, 49: 889-891.
31. Monk BC, Niimi K, Lin S, et al. Surface-active fungicidal D-peptide inhibitors of the plasma membrane proton pump that block azole resistance [J]. Antimicrob Agents Chemother, 2005, 49: 57-70.
32. Miletti KE, Leibowitz MJ. Pentamidine inhibition of group I intron splicing in Candida albicans correlates with growth inhibition [J]. Antimicrob Agents Chemother, 2000, 44: 958-966.